about
Fluorescent system based on bacterial expression of hybrid KcsA channels designed for Kv1.3 ligand screening and study.Toxins Targeting the Kv1.3 Channel: Potential Immunomodulators for Autoimmune DiseasesNovel Kv1.3 blockers for immunosuppression: WO2012155199.Perturbation of intracellular K(+) homeostasis with valinomycin promotes cell death by mitochondrial swelling and autophagic processes.Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate.Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840.State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.
P2860
Q34544160-8582CB2E-341E-4CA8-88BE-8B19D26F5696Q35662935-B35FFAE1-20B1-4E49-93F1-BA37514F2B06Q38130764-ACDD7C9E-7712-4FD7-9AD9-16B50694F7EAQ39482324-5C4E14A9-B433-437F-A5B0-40FA92071FD4Q41048502-7CF33EB8-A66F-4E8E-B7D5-723084196145Q41719973-3D356945-690C-4C0B-9CA1-51EB8CC6D9D1Q42700967-A7E99942-25BC-49DE-B873-E2714155EF98
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Use of Kv1.3 blockers for inflammatory skin conditions.
@ast
Use of Kv1.3 blockers for inflammatory skin conditions.
@en
type
label
Use of Kv1.3 blockers for inflammatory skin conditions.
@ast
Use of Kv1.3 blockers for inflammatory skin conditions.
@en
prefLabel
Use of Kv1.3 blockers for inflammatory skin conditions.
@ast
Use of Kv1.3 blockers for inflammatory skin conditions.
@en
P2093
P2860
P1476
Use of Kv1.3 blockers for inflammatory skin conditions
@en
P2093
P2860
P304
P356
10.2174/092986710792065072
P577
2010-01-01T00:00:00Z